These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 17620439

  • 1. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
    Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA.
    Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
    [Abstract] [Full Text] [Related]

  • 2. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
    Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R.
    Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554
    [Abstract] [Full Text] [Related]

  • 3. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
    Jane EP, Premkumar DR, Pollack IF.
    Mol Cancer Ther; 2011 Jan; 10(1):198-208. PubMed ID: 21220502
    [Abstract] [Full Text] [Related]

  • 4. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

  • 5. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
    Bullenkamp J, Raulf N, Ayaz B, Walczak H, Kulms D, Odell E, Thavaraj S, Tavassoli M.
    Cell Death Dis; 2014 Oct 23; 5(10):e1489. PubMed ID: 25341043
    [Abstract] [Full Text] [Related]

  • 6. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.
    Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A, Stremmel W, Walczak H.
    Hepatology; 2007 Mar 23; 45(3):649-58. PubMed ID: 17326159
    [Abstract] [Full Text] [Related]

  • 7. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
    Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, Kusukawa J, Kage M, Shirouzu K, Yamana H.
    Mol Cancer Ther; 2010 Jun 23; 9(6):1842-51. PubMed ID: 20515944
    [Abstract] [Full Text] [Related]

  • 8. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE, Rundall BK, Keller MD, Jones DR.
    Ann Thorac Surg; 2004 Oct 23; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [Abstract] [Full Text] [Related]

  • 9. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
    Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ.
    Mol Cancer Ther; 2006 Sep 23; 5(9):2251-60. PubMed ID: 16985059
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
    Ehrenschwender M, Bittner S, Seibold K, Wajant H.
    Cell Death Dis; 2014 Dec 11; 5(12):e1570. PubMed ID: 25501831
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
    Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ.
    Mol Cancer Res; 2010 May 11; 8(5):729-38. PubMed ID: 20442297
    [Abstract] [Full Text] [Related]

  • 18. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
    Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S.
    Clin Cancer Res; 2011 Jun 15; 17(12):4019-30. PubMed ID: 21525171
    [Abstract] [Full Text] [Related]

  • 19. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
    Chen M, Wang X, Zha D, Cai F, Zhang W, He Y, Huang Q, Zhuang H, Hua ZC.
    Sci Rep; 2016 Oct 18; 6():35468. PubMed ID: 27752089
    [Abstract] [Full Text] [Related]

  • 20. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
    Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, Chen PJ, Cheng AL.
    J Biol Chem; 2009 Apr 24; 284(17):11121-33. PubMed ID: 19261616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.